Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.

开始日期2026-01-06

申办/合作机构

SWOG

[+1]

NCT07094113

/ Not yet recruiting临床1期

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations.
This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts. The goal is to determine the Maximum Tolerated Dose (MTD)-the highest dose with acceptable safety and manageable side effects-or the Recommended Phase 2 Dose (RP2D) of AMG 410 in adult participants with KRAS-altered advanced or metastatic solid tumors.

开始日期2025-08-04

申办/合作机构

Amgen, Inc.

NCT07094204

/ Not yet recruiting临床1期

A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene.
ASP5834 is being studied in people with solid tumors who have certain KRAS gene mutations. Some people with solid tumors of the colon or rectum (colorectal cancer), will be given ASP5834 with panitumumab. Panitumumab is a treatment for colorectal cancer. In this study, the researchers will learn how ASP5834 is processed by and acts upon the body. This information will help find a suitable dose of ASP5834 and check for any potential medical problems from the treatment.
The main aims of this study are to check the safety of ASP5834 given by itself or given with panitumumab, and how well it is tolerated; and to find a suitable dose of ASP5834 given by itself or given with panitumumab.
People in this study will be adults with locally advanced, unresectable, or metastatic solid tumors with certain KRAS gene mutations. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. The key reasons people cannot take part are if they have specific uncontrollable cancers such as symptomatic or untreated cancers in nervous system, or have a specific heart condition, or infections.
In this study, ASP5834 is being given to humans for the first time. This is an open-label study. This means that people in this study and clinic staff will know that they will receive ASP5834 by itself or ASP5834 with panitumumab.
This study will be in 2 parts:
Part 1 is called Dose Escalation. Different small groups of people will receive lower to higher doses of either: ASP5834 by itself or ASP5834 with panitumumab. Only people who have colorectal cancer will receive ASP5834 with panitumumab. People with any type of solid tumor will receive ASP5834 by itself. For each dose, all medical problems will be recorded. A medical expert panel will check the results and decide if the next group can receive a higher dose of ASP5834. The panel will do this until the planned maximum number of people are treated or until suitable doses have been selected for Part 2.
Part 2 is called Dose Expansion. Other different small groups of people will receive ASP5834 or ASP5834 with panitumumab. They will receive the most suitable doses worked out from Part 1.
In both parts of the study, the study treatments ASP5834 and panitumumab will be given through a vein. This is called an infusion. Each study treatment cycle is either 21 days or 28 days long. People will continue study treatment until: they have medical problems from the study treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop study treatment.
People will visit the clinic on certain days during their study treatment, with extra visits during the first 2 cycles of study treatment. The study doctors will check for any medical problems from ASP5834. Also, people in the study will have a health check. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken at certain visits during study treatment with the option of a tumor sample being taken if people's cancer gets worse or the cancer comes back.
People will visit the clinic shortly after stopping treatment for a health check. After this, people will have health checks every couple of months to check the condition of their cancer. The number of visits and checks done will depend on the health of each person and whether they completed their study treatment or not. It is expected that people will be in this study for about 1 year.

开始日期2025-07-31

申办/合作机构

Astellas Pharma, Inc.

100 项与帕尼单抗相关的临床结果

登录后查看更多信息

100 项与帕尼单抗相关的转化医学

登录后查看更多信息

100 项与帕尼单抗相关的专利（医药）

登录后查看更多信息

2,471

项与帕尼单抗相关的文献（医药）

2025-12-01·Journal of Gastrointestinal Cancer

Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis

Review

作者: da Silva, Luís Felipe Leite ; Peixoto, Renata D 'Alpino ; Saldanha, Erick Figueiredo ; da Conceição, Lucas Diniz ; Noronha, Mariana Macambira ; da Silva, Marcos Vinícius Martins Grangeiro

BACKGROUND:

Metastatic colorectal cancer (mCRC) remains a significant clinical challenge. While anti-EGFR inhibitors have improved survival rates, their long-term efficacy is limited by disease progression, which is often associated with the development of acquired resistance mutations. However, some patients may regain sensitivity to anti-EGFR agents after alternative therapies, suggesting a potential benefit for rechallenge strategies. Our study aims to conduct a systematic review and meta-analysis to comprehensively evaluate the efficacy and safety of EGFR rechallenge in patients with mCRC.

METHODS:

A systematic search of the MEDLINE, EMBASE, and Cochrane databases was conducted between October 28 and December 24, 2023, to identify clinical trials investigating treatment regimens incorporating panitumumab or cetuximab as a rechallenge strategy. Pooled proportions or hazard ratios (HR) were calculated using a random effects model. Inter-study heterogeneity was assessed using the I².

RESULTS:

Among the 2105 articles identified through the search, 13 met the predetermined inclusion criteria. Of these, 12 were phase II studies, encompassing 92.3% of the patient population. Cetuximab was administered to 302 patients (75.1%), whereas panitumumab was utilized in 100 patients (24.9%).A pooled analysis of eight studies demonstrated an objective response rate of 20.50% (95% CI 7.94 to 33.07) and a disease control rate of 67.35% (95% CI 58.60 to 76.09). The median progression-free survival was estimated at 3.5 months (95% CI 2.68-6.69), with a median OS of 9.8 months (95% CI 6.71-12.89). Patients exhibiting RAS wild-type status in circulating tumor DNA (ctDNA) analysis derived enhanced benefits from anti-EGFR rechallenge (HR: 0.41; 95% CI 0.28-0.60, I² = 60%). Common grade 3 or higher treatment-related adverse events included neutropenia (22.8%) and rash (14.9%).

CONCLUSION:

This meta-analysis underscores the efficacy and safety of anti-EGFR rechallenge as a promising therapeutic approach for a subset of patients afflicted with mCRC. The observed correlation between wild-type RAS status, as determined through ctDNA analysis, and improved OS signals the prospect of precision oncology in guiding treatment decisions.

2025-12-01·Journal of Gastrointestinal Cancer

Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer

Article

作者: Zirrgiebel, Ute ; Depenbusch, Reinhard ; Müller, Lothar ; Lerchenmüller, Christian ; Boller, Emil ; Niemeier, Beate ; Marschner, Norbert ; Sahm, Stephan ; Potthoff, Karin ; Tesch, Hans

BACKGROUND:

The combination of FOLFOX/FOLFIRI with an EGFR-antibody (cetuximab/panitumumab) is a first-line standard for RAS wild-type metastatic colorectal cancer (mCRC). The OPTIMOX stop-and-go regimen, which reduces oxaliplatin-induced neuropathy, and fluorouracil/folinic acid (FU/FA) were standard maintenance-therapies in the pre-antibody era. Whether an EGFR-antibody adds value to the OPTIMOX strategy in the RAS wild-type setting remains unknown.

METHODS:

In the open-label, randomized, multicenter phase II ERBIMOX trial, patients with KRAS wild-type mCRC received either first-line induction-therapy with 8 cycles of mFOLFOX7 followed by maintenance-therapy with FU/FA (OPTIMOX arm) or mFOLFOX7 + cetuximab followed by FU/FA + cetuximab (ERBIMOX arm). Primary objective was to demonstrate superiority of additional cetuximab to mFOLFOX7 during induction/maintenance-therapy. Primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS) and safety. The trial is registered at EudraCT (No.2006-002744-28).

RESULTS:

From 2006-2011, 138 patients with KRAS wild-type mCRC from 23 German sites were randomly assigned to either OPTIMOX (N = 63) or ERBIMOX (N = 75). ORR numerically favored the ERBIMOX arm (64.0% vs. 54.0%, P = 0.3071). Median PFS (ERBIMOX vs. OPTIMOX) was 9.6 vs. 8.8 months (P = 0.7612), median OS 25.6 vs. 30.9 months (P = 0.5821). Most common grade 3/4 adverse events (AEs) were skin reactions (21.9% vs. 2.1%) and gastrointestinal disorders (13.5% vs. 9.5%). No cetuximab-related deaths occurred.

CONCLUSION:

In treatment-naïve KRAS wild-type mCRC, adding cetuximab to mFOLFOX7 resulted in numerically higher ORR than mFOLFOX alone, but no statistically significant differences in ORR, PFS or OS; probably because of the premature stop due to poor recruitment. The safety profile was as expected, with few discontinuations.

2025-12-01·Journal of Gastrointestinal Cancer

Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

Review

作者: Burbano, Rommel Mario Rodríguez ; de Oliveira Rodrigues, Anna Luíza Soares ; de Moraes, Francisco Cezar Aquino ; Limachi-Choque, Jhonny ; Priantti, Jonathan N

BACKGROUND:

Colorectal cancer (CRC) represents the second leading cause of cancer-related mortality worldwide, with a significant portion of patients presenting with metastatic disease at diagnosis. Resistance to initial anti-EGFR therapy, a key treatment for RAS wild-type metastatic CRC, remains a major challenge. This study aimed to assess the efficacy and safety of rechallenge with anti-EGFR therapy in patients with metastatic CRC who have progressed after prior treatments.

METHODS:

A systematic search was conducted across PubMed, Web of Science, Cochrane, and Scopus. Studies were included if they were randomized controlled trials (RCTs) or observational studies involving patients with EGFR-mutated metastatic CRC who received anti-EGFR therapy as a rechallenge. Endpoints included objective response rate (ORR), disease control rate (DCR), and the incidence of adverse events. Statistical analyses were performed using the DerSimonian/Laird random effect model, with heterogeneity assessed via I² statistics. R, version 4.2.3, was used for statistical analyses.

RESULTS:

Fourteen studies were included with 520 patients; 50.3% were male, and the median age was 63 years old. The median progression-free survival (mPFS) ranged between 2.4 and 4.9 months, while the median overall survival (mOS) ranged from 5 to 17.8 months. Our pooled analysis demonstrated an objective response rate (ORR) of 17.70% (95% CI, 8.58-26.82%) and a disease control rate (DCR) of 61.72% (95% CI, 53.32-70.11%), both with significant heterogeneity (I², 84% and 80%, respectively; p < 0.01). In the subgroup analysis, cetuximab showed an ORR of 18.31% (95% CI, 4.67-31.94%), and panitumumab an ORR of 10.9% (95% CI, 0.00-26.82%), while the combination of both resulted in an ORR of 29.24% (95% CI, 0.00-65.84%). For DCR, cetuximab resulted in 62.1% (95% CI, 49.32-74.87%), panitumumab in 63.05% (95% CI, 52.13-73.97%), and the combination in 60.34% (95% CI, 31.92-88.77%), all with significant heterogeneity. Adverse events included anemia (15.39%), diarrhea (4.20%), hypomagnesemia (6.40%), neutropenia (22.57%), and skin rash (13.22%).

CONCLUSIONS:

Rechallenge with anti-EGFR therapy in metastatic CRC patients shows moderate efficacy with manageable safety profiles. These findings highlight the need for careful patient selection and monitoring to optimize outcomes. Further studies are warranted to refine strategies for maximizing the therapeutic benefits of anti-EGFR rechallenge.

230

项与帕尼单抗相关的新闻（医药）

2025-07-29

·ioncology

ESMO 2025丨标题公布！消化道肿瘤领域口头报告一文速览

点击蓝字关注我们编者按2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17~21日在德国柏林盛大举行。作为全球肿瘤学领域最具影响力的学术盛会之一，本届大会将集中呈现肿瘤诊疗领域的突破性研究进展。目前，大会官网已公布除LBA（Late-breaking Abstract）摘要外的全部入选研究标题。本文系统梳理了消化系统肿瘤领域Proffered Paper session和Mini oral session部分前沿成果，涵盖结直肠癌、胃癌、肝癌、胰腺癌、神经内分泌肿瘤等主要癌种，旨在为临床工作者和研究人员构建完整的研究进展图谱。期待ESMO 2025正式召开时，更多重磅数据的发布有望为全球消化系统肿瘤诊疗实践带来革命性突破。上消化道肿瘤Proffered Paper session 摘要号：2094O英文标题：SKYSCRAPER-07: A phase Ⅲ, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT)中文标题：SKYSCRAPER-07：阿替利珠单抗（Atezo）联合或不联合Tiragolumab（Tira）治疗接受过根治性同步放化疗（dCRT）后未进展的不可切除食管鳞癌（ESCC）患者的Ⅲ期随机研究讲者：Ian Chau (Sutton, United Kingdom)Mini oral session 摘要号：2095MO 英文标题：Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma – Interim Analysis of the phase Ⅱ PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)中文标题：帕博利珠单抗联合曲妥珠单抗及FLOT方案用于HER2阳性局部食管胃腺癌围手术期治疗——AIO研究组Ⅱ期PHERFLOT/IKF-053试验的阶段性分析（AIO STO 0321）讲者：Eray Goekkurt (Hamburg, Germany)***************************************************************摘要号：2096MO英文标题：Systemic Therapy, Gastrectomy and CRS/HIPEC vs Systemic Therapy Alone for Gastric Cancer with Limited Peritoneal Dissemination: Results of the Randomised PERISCOPE Ⅱ Trial.中文标题：系统治疗、胃切除术联合CRS/HIPEC对比单纯系统治疗用于局限性腹膜播散胃癌：随机化PERISCOPE Ⅱ试验结果讲者：Judith S. Quik (Amsterdam, Netherlands)***************************************************************摘要号：1469MO英文标题：Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): a multicenter, open-label, randomized phase Ⅲ trial.中文标题：局部晚期肝细胞癌（HCC）患者接受Atezo/Bev治疗后，肝切除术对比继续Atezo/Bev治疗（TALENTop）：多中心、开放标签、随机Ⅲ期试验讲者：Hui-Chuan Sun (Shanghai, China)讲者：复旦大学附属中山医院孙惠川***************************************************************摘要号：1470MO英文标题：Perioperative Camrelizumab plus Rivoceranib in Resectable Hepatocellular Carcinoma (CARES-009): A Randomized, Multicenter, Phase 3 Trial中文标题：围手术期卡瑞利珠单抗联合瑞戈非尼治疗可切除肝细胞癌（CARES-009）：随机、多中心、Ⅲ期试验讲者：复旦大学附属中山医院周俭***************************************************************摘要号：1471MO英文标题：Adding Ipilimumab (IPI) to Atezolizumab (ATEZO) plus Bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC中文标题：伊匹木单抗（IPI）联合阿替利珠单抗（ATEZO）和贝伐珠单抗（BEV）用于不可切除肝细胞癌（uHCC）的一线系统治疗（1L）：PRODIGE 81/FFCD 2101 - TRIPLET HCC试验讲者：Philippe Merle (LYON, France)***************************************************************摘要号：2214MO 英文标题：Phase 1 basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC)中文标题：针对c-Met蛋白的抗体药物偶联物Telisotuzumab Adizutecan（ABBV-400; Temab-A）的Ⅰ期篮式研究：胰腺导管腺癌（PDAC）患者的结果讲者：James J. Harding (New York, United States of America)***************************************************************摘要号：2215MO英文标题：HRS-4642 Combined with Gemcitabine and Nab-paclitaxel in KRAS-G12D Mutant Advanced Pancreatic Cancer: A Phase 1b/2 Study中文标题：HRS-4642联合吉西他滨和白蛋白结合型紫杉醇治疗KRAS-G12D突变晚期胰腺癌：1b/2期研究讲者：上海交通大学医学院附属仁济医院王理伟教授***************************************************************摘要号：2216MO英文标题：VIRAGE trial: randomized Phase Ⅱb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)中文标题：VIRAGE试验：随机Ⅱb期、开放标签研究，评估白蛋白结合型紫杉醇联合吉西他滨±静脉VCN-01治疗转移性胰腺癌（mPDAC）讲者：Rocio Garcia-Carbonero (Madrid, Spain)下消化道肿瘤Proffered paper session摘要号：726O英文标题：Prognostic value of the Combined Analysis of Pathologists and Artificial Intelligence (CAPAI) in high-risk stage Ⅱ-Ⅲ colon cancer treated without chemotherapy: interim report from a nationwide validation中文标题：病理学家与人工智能联合分析（CAPAI）对未接受化疗的高危Ⅱ-Ⅲ期结肠癌的预后价值：全国验证的阶段性报告讲者：Marie-Christine E. Bakker (Utrecht, Netherlands)***************************************************************摘要号：723O英文标题：Post-surgical liquid biopsy-guided treatment of stage Ⅲ and high-risk stage Ⅱ colon cancer patients: final results of the PEGASUS trial.中文标题：术后液体活检指导的Ⅲ期及高危Ⅱ期结肠癌治疗：PEGASUS试验最终结果讲者：Silvia Marsoni (Milan, Italy, (TO))***************************************************************摘要号：724O英文标题：Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2中文标题：局部晚期dMMR结肠癌临床试验结果比较：FOxTROT与NICHE-2讲者：Jenny Seligmann (Leeds, United Kingdom, Yorkshire)***************************************************************摘要号：725O英文标题：Leveraging Artificial Intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: translational analyses of AtezoTRIBE and AVETRIC trials中文标题：利用人工智能预测免疫检查点抑制剂（ICI）在MMR熟练型转移性结直肠癌（mCRC）中的疗效：AtezoTRIBE和AVETRIC试验的转化分析讲者：Martina Carullo (Pisa, Italy)Mini oral session摘要号：1MO英文标题：Placental features overexpression reveals hidden facets of early-onset colorectal cancer中文标题：胎盘特征过度表达揭示早发性结直肠癌的隐藏面讲者：Gianluca Mauri (Milan, Italy)***************************************************************摘要号：727MO英文标题：FOLFOX plus PANITUMUMAB (Pmab) according to a “stop-and-go” strategy in first-line in patients (pts) with non-mutated RAS/BRAF metastatic colorectal cancer (mCRC). Results of the FFCD 1605 – OPTIPRIME phase Ⅱ trial.中文标题： FOLFOX联合帕尼单抗（Pmab）"stop-and-go"策略治疗RAS/BRAF野生型转移性结直肠癌（mCRC）患者的一线治疗：FFCD 1605-OPTIPRIME Ⅱ期试验结果讲者：Jean-Baptiste Bachet (Paris, France)***************************************************************摘要号：728MO英文标题：Predictive Value of Low-Frequency Resistance Mutations and Relative Mutant Allele Frequencies (rMAFs) in Anti-EGFR Rechallenge for RAS/BRAF Wild-Type (wt) Metastatic Colorectal Cancer (mCRC)中文标题：低频耐药突变及相对突变等位基因频率（rMAFs）在RAS/BRAF野生型转移性结直肠癌（mCRC）抗EGFR再挑战中的预测价值讲者：Pau Mascaró Baselga (Barcelona, Spain)***************************************************************摘要号：729MO英文标题：Circulating tumor (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER中文标题：循环肿瘤（ct）DNA分析BRAF V600E动态及基因组图谱变化：BREAKWATER试验中一线（1L）BRAF V600E突变转移性结直肠癌（mCRC）患者讲者：Scott Kopetz (Houston, United States of America)***************************************************************摘要号：730MO英文标题：Trifluridine/Tipiracil in combination with Capecitabine and Bevacizumab as upfront treatment for metastatic colorectal cancer: first results of the phase Ⅱ TriComB study by GONO中文标题：曲氟尿苷/替匹嘧啶联合卡培他滨和贝伐珠单抗作为转移性结直肠癌的初始治疗：GONO Ⅱ期TriComB研究的初步结果讲者：Veronica Conca (Pisa, Italy)***************************************************************摘要号：731MO英文标题：Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase 1 study中文标题：Telisotuzumab Adizutecan（ABBV-400; Temab-A）联合贝伐珠单抗（Bev）对比标准治疗（SOC）用于3线及以上结直肠癌（CRC）：Ⅰ期研究剂量扩展结果讲者：Michael Cecchini (New Haven, United States of America)神经内分泌肿瘤与内分泌肿瘤Proffered Paper session摘要号：1705O英文标题：LITESPARK-015: Belzutifan in advanced pheochromocytoma and paraganglioma中文标题：LITESPARK-015：Belzutifan治疗晚期嗜铬细胞瘤和副神经节瘤讲者：Camilo Jimenez (Houston, United States of America)***************************************************************摘要号：1706O英文标题：Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial中文标题：177Lu-edotreotide对比依维莫司治疗1~2级胃肠胰神经内分泌肿瘤（GEP-NETs）的疗效、安全性及亚组分析：Ⅲ期COMPETE试验讲者：Jaume Capdevila (Barcelona, Spain)***************************************************************摘要号：2987O英文标题：Efficacy and Safety of Dabrafenib Plus Trametinib (D+T) in Patients With Radioactive Iodine (RAI)-Refractory BRAF V600-Mutant Differentiated Thyroid Cancer (DTC)中文标题：达拉非尼联合曲美替尼（D+T）治疗放射性碘（RAI）难治性BRAF V600突变分化型甲状腺癌（DTC）的疗效与安全性讲者：津市人民医院高明教授Mini oral session摘要号：1707MO英文标题：A Phase 2 Dose Expansion Study of ZG006, a Trispecific T Cell Engager Targeting DLL3/DLL3/CD3, as Monotherapy in Patients with Refractoy Neuroendocrine Carcinoma中文标题：ZG006（靶向DLL3/DLL3/CD3的三特异性T细胞衔接器）单药治疗难治性神经内分泌癌的Ⅱ期剂量扩展研究讲者：中国人民解放军总医院赵传华***************************************************************摘要号：1708MO英文标题：ZG005 in combination with etoposide and cisplatin for the first-line treatment of advanced neuroendocrine carcinoma中文标题：ZG005联合依托泊苷和顺铂用于晚期神经内分泌癌的一线治疗讲者：Sisi Ye (Beijing, China)***************************************************************摘要号：1709MO英文标题：Multi-center NCI-sponsored phase 1 study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)中文标题：多中心NCI资助的Ⅰ期研究：Triapine联合177Lu-dotatate治疗分化良好的胃肠胰神经内分泌肿瘤（GEP-NETs）讲者：Aman Chauhan (Deerfield Beach, United States of America)***************************************************************摘要号：1033MO英文标题：[212Pb]VMT-α-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2 positive (SSTR2+) neuroendocrine tumours (NETs): mature safety and preliminary efficacy for enrollment from dose-finding cohorts 1 and 2 (n=44)中文标题：[212Pb]VMT-α-NET靶向α粒子治疗（TAT）用于晚期生长抑素受体2阳性（SSTR2+）神经内分泌肿瘤（NETs）：剂量探索队列1和2（n=44）的成熟安全性和初步疗效讲者：Thorvardur R. Halfdanarson (Rochester, United States of America)***************************************************************摘要号：1034MO英文标题：Long-term Follow-up of Peptide Receptor Radionuclide Therapy (PRRT)-Naïve Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Treated with Targeted Alpha Therapy 212Pb-DOTAMTATE in the Phase 2 ALPHAMEDIX 02 Trial中文标题：212Pb-DOTAMTATE靶向α治疗在未接受过肽受体放射性核素治疗（PRRT）的胃肠胰腺神经内分泌肿瘤（GEP-NETs）患者中的长期随访：一项Ⅱ期ALPHAMEDIX 02临床试验结果讲者：Jonathan R. Strosberg (Tampa, United States of America)***************************************************************摘要号：1035MO英文标题：A Prediction Tool for Malnutrition and Sarcopenia in Patients with Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs): Results from NUTRIGETNE (GETNE-S2109) Study中文标题：胃肠胰神经内分泌肿瘤（NENs）患者营养不良和肌肉减少症的预测工具：NUTRIGETNE（GETNE-S2109）研究结果讲者：Maribel Del Olmo (Valencia, Spain)***************************************************************摘要号：1710MO英文标题：Belzutifan for Advanced Pancreatic Neuroendocrine Tumors (panNETs): Results From Cohort A2 of the Phase 2 LITESPARK-015 Study中文标题：Belzutifan治疗晚期胰腺神经内分泌肿瘤（panNETs）：Ⅱ期LITESPARK-015研究A2队列结果讲者：Jaume Capdevila (Barcelona, Spain)***************************************************************摘要号：2988MO英文标题：Patient-Derived Organoids Predict Clinical Response and Guide Personalized Therapy in Advanced Thyroid Cancer中文标题：患者来源的类器官预测晚期甲状腺癌临床反应并指导个性化治疗讲者：Jiaye Liu (Chengdu, China)（来源：肿瘤瞭望消化时讯）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床2期临床3期临床结果临床成功

2025-07-29

·医药笔记

Celcuity大涨167%：PI3K/Akt/mTOR抑制剂乳腺癌三期临床成功

▎Armstrong2025年7月28日，Celcuity宣布其PI3K/Akt/mTOR抑制剂Gedatolisib在治疗PI3KCA野生型、HR+/HER2-乳腺癌的三期临床中达到具有临床意义的PFS改善终点。Celcuity当天股价大涨167%，市值达到14亿美元。PI3K/Akt/mTOR（PAM）的反馈loops为实体瘤的驱动基因通路，且不同PI3K亚型、AKT、mTOR之间存在冗余本来保证信号过通路通能，因此只抑制一个靶点效力有限，故而第一代的PAM都是pan-PI3K/mTOR抑制剂，但其毒性较大，经过不断地迭代，终于开发出今天更安全、活性更强的pan-PI3K/Akt/mTOR抑制剂。PAM为实体瘤中最被低估的靶点，其突变率在主要实体瘤中高达38%，高于HER2（主要在乳腺癌）、EGFR（主要在肺癌）、ALK（主要在肺癌）。Gedatolisib为一款高度差异化的分子，同时抑制不同PI3K亚型、mTOR、AKT，作用机制区别于Alpelisib、依维莫司、Capivasertib等。Gedatolisib的安全性也显著优于单靶点的竞品分子。的此次公开数据的三期临床VIKTORIA-1方案设计如下，此次公开的为PI3KCA野生型部分，拟入组351例，三个队列分为为Gedatolisib+Palbociclib+氟维司群三联疗法、Gedatolisib+氟维司群二联疗法、氟维司群单药对照组，主要终点为PFS。VIKTORIA-1实际入组392例。三联疗法队列mPFS为9.3个月，氟维司群对照组mPFS为2.0个月，mPFS延长7.3个月，疾病进展或死亡风险降低76%，p＜0.0001。二联疗法队列mPFS为7.4个月，氟维司群对照组mPFS为2.0个月，mPFS延长5.4个月，疾病进展或死亡风险降低67%，p＜0.0001。与竞品相比，Gedatolisib三联和二联疗法二线治疗的mPFS都具有明显优势。与内分泌治疗相比的mPFS延长幅度，为目前最佳临床数据。HR值更是提高到一个新的水平。总结Celcuity预计今年四季度递交上市申请，针对PI3KCA突变人群队列的临床数据预计今年底读出。PI3K/Akt/mTOR三期临床大获成功意味着HR+/HER2-乳腺癌领域的重大进展，也意味着PAM多靶点抑制剂的里程碑，更多国产PAM或将迎来出海热潮。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床3期临床2期抗体药物偶联物

2025-07-24

·Business Wire

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager (TCE) targeting EGFR (epidermal growth factor receptor). VIR-5525 will be evaluated for the treatment of a variety of EGFR-expressing solid tumors in areas of high unmet need such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and cutaneous squamous cell carcinoma (cSCC). The Phase 1 clinical trial (NCT06960395) is a first-in-human open-label, non-randomized study designed to assess the safety, pharmacokinetics, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab. VIR-5525 is Vir Biotechnology’s third dual-masked TCE in clinical trials. It incorporates the Company’s clinically validated in-licensed PRO-XTEN™ masking technology, which is designed to enable the selective activation of the TCEs in the tumor microenvironment, mitigating damage to healthy cells and reducing toxicity. EGFR is a clinically validated target known to play a key role in cancer.1 Although EGFR-targeting therapies are available, they often face limitations due to the development of resistance mechanisms2 and high toxicities associated with treatment.3 “We are excited to bring our third PRO-XTEN™ dual-masked T-cell engager VIR-5525 to the clinic as we further our mission of transforming the lives of people living with hard-to-treat solid tumors,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “This achievement is a testament of Vir Biotechnology’s commitment to advancing innovative therapies that address substantial unmet needs in oncology.” “EGFR has been well characterized as a key oncogenic driver and a marker of poor prognosis in cancer. Traditional therapies have significant limitations, creating a substantial unmet need for highly efficacious and well-tolerated options,” said Mark Eisner, MD, MPH, Chief Medical Officer, Vir Biotechnology. “VIR-5525 harnesses the anti-tumor power of T-cell engagers with a dual-masking approach designed to unlock an expanded therapeutic index. We look forward to evaluating the potential of this clinical candidate in our Phase 1 trial.” The first patient dosing of VIR-5525 triggers a $75 million milestone payment as part of the Company's 2024 exclusive worldwide license agreement with Sanofi for the PRO-XTEN™ platform and clinical-stage T-cell engagers. This anticipated milestone payment has been held as restricted cash since the transaction closing and was excluded from the Company’s $1.02 billion in cash, cash equivalents and investments reported as of March 31, 2025. The payment will be recognized as a research and development expense in the third quarter of 2025. Dose escalation continues for Vir Biotechnology’s dual-masked TCEs VIR-5818 (targeting a variety of HER2-expressing solid tumors) and VIR-5500 (targeting PSMA in metastatic castration-resistant prostate cancer). Initial Phase 1 data presented in January 2025 showed compelling early clinical response signals and promising safety profiles for both clinical candidates in heavily pretreated patients. The Company is advancing multiple preclinical dual-masked TCEs against clinically validated targets with potential applications across a variety of solid tumors with high unmet need. These undisclosed candidates integrate the PRO-XTEN™ masking technology with novel TCEs discovered and engineered using Vir Biotechnology’s antibody discovery platform and the Company’s proprietary dAIsY™ (data AI structure and antibody) artificial intelligence engine. About VIR-5525 T-cell engagers (TCEs) are powerful anti-tumor agents that can direct the immune system, specifically T-cells, to destroy cancer cells. VIR-5525 is an investigational dual-masked TCE currently being evaluated in an open-label, non-randomized Phase 1 clinical trial (NCT06960395) designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combination with pembrolizumab. VIR-5525 combines a bispecific EGFR and CD3 binding TCE with the PRO-XTEN™ masking technology. The PRO-XTEN™ masking technology is designed to keep the TCEs inactive (or masked) until they reach the tumor microenvironment, where tumor-specific proteases cleave off the mask and activate the TCEs, leading to killing of cancer cells by T-cells. By confining the activity exclusively to the tumor microenvironment, we aim to circumvent the traditionally high toxicity associated with unmasked TCEs and increase their efficacy and tolerability. Additionally, the mask is designed to help drug candidates stay in the bloodstream longer in their inactive form, allowing them to better reach the site of action and potentially allowing for less frequent dosing regimens. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Vir Biotechnology has exclusive rights to the PRO-XTEN™ masking platform for oncology and infectious disease. PRO-XTEN™ is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company. References: 1 Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2017 Nov 27;12(1):3–20. 2 Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 013 Jan 28;14(4):304–314. 3 Zhao Y, Cheng B, Chen Z, Li J, Liang H, Chen Y, Zhu F, Li C, Xu K, Xiong S, Lu W, Chen Z, Zhong R, Zhao S, Xie Z, Liu J, Liang W, He J. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2021 Apr; 160:103305; Liu T, Jiang S, Teng X, Zhong L, Liu M, Jin Y, Dong M. A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Immunopharmacol Immunotoxicol. 2023 Feb; 45(1):1-9. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “should,” “could,” “may,” “might,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding: the therapeutic potential of VIR-5525, both as a monotherapy and in combination with pembrolizumab, as a treatment for a variety of EGFR-expressing solid tumors in areas of high unmet need, and Vir Biotechnology’s belief that VIR-5525 and the PRO-XTEN™ masking technology can circumvent the traditionally high toxicity associated with unmasked TCEs and unlock an expanded therapeutic index; Vir Biotechnology’s preclinical and clinical development plans and expectations for its TCE assets, including protocols for and enrollment into ongoing and planned clinical studies, potential dosing regimens, target endpoints and data readouts; Vir Biotechnology’s delivery and recognition of the $75 million milestone payment pursuant to the 2024 exclusive worldwide license agreement with Sanofi; Vir Biotechnology’s strategy and plans; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation: unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; challenges in accessing manufacturing capacity; clinical site activation rates or clinical enrollment rates that are lower than expected; the timing and outcome of Vir Biotechnology’s planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals; successful development and/or commercialization of alternative product candidates by Vir Biotechnology’s competitors, as well as changes in expected or existing competition; Vir Biotechnology’s use of artificial intelligence and machine learning in its efforts to engineer next-generation proteins and in other research and development efforts; geopolitical changes or other external factors; and unexpected litigation or other disputes. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later-stage or larger-scale clinical studies and do not ensure regulatory approval. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on any scientific data presented or these forward-looking statements, which are based on Vir Biotechnology’s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

临床1期引进/卖出

100 项与帕尼单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05350	帕尼单抗	L01XC08	DB01269

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
KRAS G12C突变结直肠癌	美国	Amgen, Inc.	2025-01-16
KRAS 野生型结直肠癌	美国	Amgen, Inc.	2014-05-23
结直肠癌	日本	Takeda Pharmaceutical Co., Ltd.	2010-04-16
RAS 野生型结直肠癌	澳大利亚	Amgen Australia Pty Ltd.	2008-05-14
转移性结直肠癌	美国	Amgen, Inc.	2006-09-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
大肠腺癌	临床3期	美国	Amgen, Inc.	2018-02-27
遗传性非息肉病性结直肠癌1型	临床3期	美国	Amgen, Inc.	2018-02-27
NRAS 野生型结直肠癌	临床3期	日本	Takeda Pharmaceutical Co., Ltd.	2015-05-29
转移性食管鳞状细胞癌	临床3期	德国	Amgen, Inc.	2012-05-01
KRAS 突变结直肠癌	临床3期	美国	Amgen, Inc.	2010-02-02
KRAS 突变结直肠癌	临床3期	澳大利亚	Amgen, Inc.	2010-02-02
KRAS 突变结直肠癌	临床3期	比利时	Amgen, Inc.	2010-02-02
KRAS 突变结直肠癌	临床3期	加拿大	Amgen, Inc.	2010-02-02
KRAS 突变结直肠癌	临床3期	捷克	Amgen, Inc.	2010-02-02
KRAS 突变结直肠癌	临床3期	法国	Amgen, Inc.	2010-02-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EUCTR2016-001490-33-FR (PANIRINOX-UCGI28, ESMO_GI2025)	临床2期	RAS/BRAF wild-type \| circulating DNA (cirDNA)	-	Panitumumab + FOLFIRINOX	觸積觸網齋遞簾鏇遞繭(鹹鹹廠製獵廠襯觸廠鏇) = 繭鑰壓觸範選衊膚構糧遞淵齋願鹹廠憲鹽蓋鑰 (顧廠醖蓋鹹遞選鏇願網 ) 更多	不佳	2025-07-05
EUCTR2016-001490-33-FR (PANIRINOX-UCGI28, ESMO_GI2025)	临床2期	RAS/BRAF wild-type \| circulating DNA (cirDNA)	-	Panitumumab + mFOLFOX6	觸積觸網齋遞簾鏇遞繭(鹹鹹廠製獵廠襯觸廠鏇) = 鑰構廠鹹簾襯鏇憲憲襯遞淵齋願鹹廠憲鹽蓋鑰 (顧廠醖蓋鹹遞選鏇願網 ) 更多	不佳	2025-07-05
BEACON and BREAKWATER (ESMO_GI2025)	N/A	BRAF V600E突变结直肠癌二线 \| 三线 BRAF V600E	43	Panitumumab plus Encorafenib	鹹鑰醖構憲鬱鹽醖淵鹽(壓憲獵鹹鹹鬱築廠憲繭) = 7% 襯選鹽製餘繭鏇願築選 (鏇壓蓋顧淵鏇鑰範蓋壓 ) 更多	积极	2025-07-03
AGEO group (ESMO_GI2025)	N/A	BRAF V600E突变结直肠癌	20	Cetuximab (CET)	蓋製遞範壓願網鬱觸醖(廠壓鹽膚繭鬱簾衊夢構) = 5% 壓夢襯襯簾蓋襯選鏇糧 (簾鹽繭選衊廠製餘壓鹽 ) 更多	积极	2025-07-03
NCT05198934 (CodeBreaK 300 \| CodeBreak300, NEWS \| Pubmed) 人工标引	临床3期	KRAS G12C突变结直肠癌 KRAS G12C	160	960 mg索托拉西布联合帕尼单抗	鏇襯製衊鏇觸膚範觸餘(鹽獵製淵範淵淵醖遞選) = 壓鬱繭艱齋網壓糧積鏇遞憲衊廠窪鬱襯製構鹹 (糧蓋積壓獵遞築願鹹積 ) 更多	积极	2025-05-07
	临床3期	KRAS G12C突变结直肠癌 KRAS G12C	160	240 mg索托拉西布联合帕尼单抗	鏇襯製衊鏇觸膚範觸餘(鹽獵製淵範淵淵醖遞選) = 簾夢鬱夢淵齋遞淵壓餘遞憲衊廠窪鬱襯製構鹹 (糧蓋積壓獵遞築願鹹積 ) 更多	积极	2025-05-07
NCT01814501 (CTgov)	临床2期	印戒细胞癌 \| 粘液腺癌 \| 复发性结肠癌 ... 更多	16	Leucovorin Calcium+irinotecan hydrochloride+fluorouracil+panitumumab	醖鬱鹹淵齋鹽齋製鬱構(網糧膚選壓餘蓋衊憲鹽) = 構憲衊衊膚窪憲選願齋夢糧網製夢艱餘鹽範簾 (窪壓醖鹹選築鹹窪鏇衊, 選鑰製憲觸糧鑰膚鬱網 ~ 願遞顧願襯淵選鬱獵艱) 更多	-	2025-02-05
NCT04117945 (CTgov)	临床2期	遗传性非息肉病性结直肠癌1型 \| 转移性结直肠癌	22	Regorafenib (Arm A (Regorafenib))	築衊繭醖願鬱願窪壓襯(廠願簾鬱願廠襯築積襯) = 簾顧範憲獵遞鏇糧獵顧構構鹹製積艱鑰獵願鬱 (憲膚鏇淵鏇築簾蓋醖鏇, 網糧鏇襯艱繭蓋齋糧餘 ~ 窪鹽衊遞鏇廠窪觸製衊) 更多	-	2024-09-27
NCT04117945 (CTgov)	临床2期	遗传性非息肉病性结直肠癌1型 \| 转移性结直肠癌	22	Cetuximab+Irinotecan+Panitumumab (Arm B (Cetuximab, Panitumumab, Irinotecan))	築衊繭醖願鬱願窪壓襯(廠願簾鬱願廠襯築積襯) = 餘淵淵衊淵膚鹹積築鏇構構鹹製積艱鑰獵願鬱 (憲膚鏇淵鏇築簾蓋醖鏇, 選膚顧獵艱鑰膚鑰簾顧 ~ 網顧醖獵醖鏇製襯襯繭) 更多	-	2024-09-27
NCT03043950 (VALIDATE, ESMO2024) 人工标引	N/A	RAS 野生型结直肠癌一线	611	Panitumumab plus FOLFIRI/FOLFOX	醖獵夢齋鹽醖鑰築繭鏇(築窪遞鹽壓鏇簾顧衊齋) = 艱築蓋獵鬱鏇願積遞遞鑰獵鏇築窪鑰築膚網繭 (衊願鹽餘齋範餘憲築齋, 24.8 ~ 29.2) 更多	积极	2024-09-16
NCT04185883 (CodeBreaK 101, ESMO2024) 人工标引	临床1期	KRAS G12C突变结直肠癌一线 KRAS G12C–mutated	40	Sotorasib (soto) + Panitumumab (pani) + FOLFIRI	壓觸衊艱艱顧壓鬱壓廠(簾餘鏇醖網鏇獵夢簾蓋) = 構餘選構獵襯夢鑰餘衊膚遞觸壓衊顧膚積齋簾 (艱鑰憲膚襯鬱壓範廠構 ) 更多	积极	2024-09-15
NCT01581840 (FFCD 0904, CTgov)	临床1/2期	肛门鳞状细胞癌 \| 肛门上皮内瘤变	45	radiochemotherapy+Panitumumab	醖鹽鹹構醖顧鬱築夢網 = 蓋獵顧淵齋衊壓願襯簾膚糧夢鏇製艱觸選窪遞 (網構艱壓襯艱襯襯醖網, 壓壓夢觸糧鬱憲窪遞淵 ~ 膚觸鏇膚衊齋蓋憲淵鬱) 更多	-	2024-07-01
NCT04737187 \| NCT05198934 \| NCT04185883 (SUNLIGHT, ESMO_GI2024) 人工标引	N/A	转移性结直肠癌	-	Sotorasib 960mg (soto960) Plus Panitumumab (pani)	鹹築簾艱醖顧壓襯壓壓(鑰選襯衊廠窪獵餘壓觸) = 淵願淵鑰鑰壓製鏇製窪製憲壓顧積範廠膚築膚 (壓繭範獵觸鏇糧壓鏇鹽 ) 更多	积极	2024-06-27
	N/A	转移性结直肠癌	-	Trifluridine/Tipiracil(T/T) PlusBevacizumab (bev)	鹹築簾艱醖顧壓襯壓壓(鑰選襯衊廠窪獵餘壓觸) = 衊鑰窪遞糧範願壓選範製憲壓顧積範廠膚築膚 (壓繭範獵觸鏇糧壓鏇鹽 ) 更多	积极	2024-06-27